financetom
Business
financetom
/
Business
/
US FDA approves Neurocrine Biosciences' genetic disorder drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA approves Neurocrine Biosciences' genetic disorder drug
Dec 13, 2024 3:05 PM

Dec 13 (Reuters) - The U.S. Food and Drug Administration has approved Neurocrine

Biosciences' ( NBIX ) drug to treat a type of genetic disorder, the health regulator's website

showed on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Barclays Q1 profit falls 12% as mortgage competition, deals drought hit
Barclays Q1 profit falls 12% as mortgage competition, deals drought hit
Apr 24, 2024
LONDON (Reuters) -Barclays reported a 12% fall in first quarter profit on Thursday, as a squeeze on UK mortgage pricing, lower income from trading and a drought of M&A fees showed the difficulties it will face in delivering its first strategic revamp in a decade. The British bank reported pretax profit for the January-March period of 2.277 billion pounds ($2.84...
AstraZeneca beats revenue, profit estimates on resilient demand
AstraZeneca beats revenue, profit estimates on resilient demand
Apr 24, 2024
(Reuters) -AstraZeneca ( AZN ) reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs and steady growth in revenue from partnered medicines. Its pipeline of new drugs, including blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes, coupled with resilient demand in...
BNP Paribas profit tops estimates on lower costs and global banking
BNP Paribas profit tops estimates on lower costs and global banking
Apr 24, 2024
PARIS (Reuters) -BNP Paribas reported a fall in first-quarter profit and revenue on Thursday but beat analyst forecasts, as lower expenses and a strong performance in its corporate banking business offset flat or falling revenues elsewhere. The euro zone's biggest bank said group net income over the first three months of the year declined by 2.2% from a year earlier...
Hermes Q1 sales jump 17% on growth across regions
Hermes Q1 sales jump 17% on growth across regions
Apr 24, 2024
PARIS (Reuters) - Birkin bag maker Hermes reported a 17% surge in first-quarter sales on Thursday, sustaining a rapid growth rate from the previous quarter and underlining strong demand for high end luxury. Sales rose to 3.81 billion euros ($4.08 billion) for the three months to March 31 and beat expectations for a 13% rise, according to consensus provider Visible...
Copyright 2023-2025 - www.financetom.com All Rights Reserved